scholarly journals In Silico Optimization of Atrial Fibrillation-Selective Sodium Channel Blocker Pharmacodynamics

2012 ◽  
Vol 102 (5) ◽  
pp. 951-960 ◽  
Author(s):  
Martin Aguilar-Shardonofsky ◽  
Edward J. Vigmond ◽  
Stanley Nattel ◽  
Philippe Comtois
Keyword(s):  
Atrial Fibrillation ◽  
Sodium Channel ◽  
In Silico ◽  
Channel Blocker ◽  
Sodium Channel Blocker

scholarly journals Widening of the Excitable Gap and Enlargement of the Core of Reentry During Atrial Fibrillation With a Pure Sodium Channel Blocker in Canine Atria

Circulation ◽  
2003 ◽  
Vol 107 (6) ◽  
pp. 905-910 ◽  
Author(s):  
Ayaka Kawase ◽  
Takanori Ikeda ◽  
Kazuo Nakazawa ◽  
Takashi Ashihara ◽  
Tsunetoyo Namba ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Sodium Channel ◽  
Channel Blocker ◽  
Sodium Channel Blocker ◽  
The Core ◽  
Excitable Gap

scholarly journals Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker Antiarrhythmic Drugs

2020 ◽  
Vol 5 (1) ◽  
pp. 57 ◽  
Author(s):  
Aylin Ornelas-Loredo ◽  
Shinwan Kany ◽  
Vihas Abraham ◽  
Zain Alzahrani ◽  
Faisal A. Darbar ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Sodium Channel ◽  
Antiarrhythmic Drugs ◽  
Channel Blocker ◽  
Sodium Channel Blocker

Voltage Gated Sodium Channel Blockers: Synthesis of Mexiletine Analogues and Homologues

2020 ◽  
Vol 27 ◽  
Author(s):  
Alessia Catalano ◽  
Carlo Franchini ◽  
Alessia Carocci
Keyword(s):  
Sodium Channel ◽  
Channel Blocker ◽  
Parent Compound ◽  
Channel Blockers ◽  
Sodium Channel Blocker ◽  
Starting Point ◽  
Channel Blocking ◽  
Blocking Activity ◽  
Synthetic Routes ◽  
Lateral Sclerosis

: Mexiletine is an antiarrhythmic drug belonging to IB class, acting as sodium channel blocker. Besides its well-known activity on arrhythmias, its usefulness in the treatment of myotonia, myotonic distrophy and amyotrophic lateral sclerosis is now widely recognized. Nevertheless, it has been retired from the market in several countries because of its undesired effects. Thus, several papers were reported in the last years about analogues and homologues of mexiletine being endowed with a wider therapeutic ratio and a more selectivity of action. Some of them showed sodium channel blocking activity higher than the parent compound. It is noteworthy that mexiletine is used in therapy as a racemate even though a difference in the activities of the two enantiomers were widely demonstrated, with (–)-(R)-enantiomer being more active: this finding led several research groups to study mexiletine and its analogues and homologues in their optically active forms. This review summarizes the different synthetic routes used to obtain these compounds. They could represent an interesting starting point to new mexiletine-like compounds without common side effects related to the use of mexiletine.

scholarly journals B-PO04-024 PREDICTION OF A POSITIVE SODIUM CHANNEL BLOCKER PROVOCATION TEST IN PATIENTS SUSPECTED OF BRUGADA SYNDROME

Heart Rhythm ◽  
2021 ◽  
Vol 18 (8) ◽  
pp. S289
Author(s):  
Martijn Hendrik van der Ree ◽  
Jeroen Vendrik ◽  
Tom E. Verstraelen ◽  
Jan A. Kors ◽  
Ahmad S. Amin ◽  
...  
Keyword(s):  
Sodium Channel ◽  
Brugada Syndrome ◽  
Channel Blocker ◽  
Provocation Test ◽  
Sodium Channel Blocker

scholarly journals From Plastic-Bottle-Toxin to Sodium Channel Blocker: A New Role for Bisphenol A

2010 ◽  
Vol 98 (3) ◽  
pp. 114a
Author(s):  
Angelika Lampert ◽  
Andrias O. O'Reilly ◽  
B.A. Wallace ◽  
Christian Alzheimer
Keyword(s):  
Bisphenol A ◽  
Sodium Channel ◽  
Channel Blocker ◽  
Sodium Channel Blocker ◽  
Plastic Bottle
Sign in / Sign up

Export Citation Format

Share Document